van de Stadt EA, Yaqub M, Lammertsma AA, et al. - Researchers investigated if non-small cell lung cancer (NSCLC) patients with common and uncommon epidermal growth factor receptor (EGFR) mutations could be identified by ¹⁸ F-afatinib positron emission tomography (PET)/CT. Also, the link between tumor ¹⁸ F-afatinib uptake and response to afatinib therapy was assessed. This study included 12 patients: 6 EGFR wild type (WT), 3 EGFR common and 3 EGFR uncommon mutations. These underwent ¹⁸ F-afatinib PET/CT. A total of 21 tumors were detected. Findings revealed that tumors with EGFR mutations (common and uncommon) exhibited higher ¹⁸ F-afatinib uptake compared with WT. Response to therapy was best predicted by a TBR_WB _60-90 (tumor-to-whole blood activity ratio 60-90 minutes post-injection) cut-off of 6. Findings indicate that EGFR mutation positive patients for whom afatinib therapy is beneficial could be identified by using ¹⁸ F-afatinib PET/CT.